FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2977189738> ?p ?o ?g. }

• W2977189738 endingPage "2847" @default.
• W2977189738 startingPage "2844" @default.
• W2977189738 abstract "Objective: To evaluate the efficacy and safety of Anlotinib as a third-line therapy in patients with metastatic colorectal cancer. Methods: Anlotinib was administered to patients with advanced colorectal cancer who had received ≥ second-line standardized treatment, with 12 mg daily lasting for 2 weeks and withdrawal of drugs for a week. The relevant clinical information and treatment protocols were recorded.The efficacy and safety of anlotinib were followed up. Results: A total of 26 patients were enrolled in the study group, and 24 patients could be evaluated, including 2 cases of partial response (PR) and 16 cases of stable disease (SD).The object response rate (ORR) and disease control rate (DCR) were 8.3% and 75%, respectively. The median progression-free survival (PFS) and overall survival (OS) was 4.3 months (95% CI: 2.9-5.7 months) and 14.7 months (95% CI: 10.0-19.4 months), respectively. The most common adverse reactions were fatigue in 17 cases (17/26) and hand-foot skin reactions in 16 cases (16/26). Analysis of Kaplan-Meier revealed that without liver metastasis (95% CI: 11.7-32.3, P=0.011) and left-sided colonic cancer (95% CI: 11.7-46.1, P=0.014) were related to longer OS. Conclusion: Anlotinib as a third-line therapy for advanced colorectal cancer is feasible with high disease control rate and minor side effects.目的： 观察盐酸安罗替尼胶囊用于晚期转移性结直肠癌患者的临床疗效和安全性。 方法： 选择2016年1月至2018年8月安徽医科大学第二附属医院肿瘤内科收治的既往曾接受过≥二线标准化疗的晚期结直肠癌患者，给予盐酸安罗替尼胶囊，1次/d，每次12 mg，连续用药2周停1周。记录相关临床信息、治疗方案并随访疗效和安全性，分析预后影响因素。 结果： 共入组26例患者，可评效24例，部分缓解（PR）2例，疾病稳定（SD）16例，疾病控制率（DCR）为75%。中位无进展生存时间（PFS）为4.3个月（95% CI: 2.9~5.7个月），中位总生存时间（OS）为14.7个月（95% CI: 10.0~19.4个月）；最常见不良反应为乏力17例（17/26）和手足皮肤反应16例（16/26）；采用Kaplan-Meier法绘制生存曲线并行Log-rank检验，无肝转移患者（95% CI: 11.7~32.3，P=0.011）、左半结肠（95%CI：11.7~46.1，P=0.014）与较长的OS有关。 结论： 盐酸安罗替尼三线及后线治疗晚期结直肠癌的近期疾病控制率较高，不良反应可耐受。." @default.
• W2977189738 created "2019-10-03" @default.
• W2977189738 creator A5000057889 @default.
• W2977189738 creator A5007398061 @default.
• W2977189738 creator A5027112610 @default.
• W2977189738 creator A5057258673 @default.
• W2977189738 date "2019-09-24" @default.
• W2977189738 modified "2023-10-07" @default.
• W2977189738 title "[Efficacy and safety of Anlotinib as a third-line chemotherapy for metastatic colorectal cancer]." @default.
• W2977189738 doi "https://doi.org/10.3760/cma.j.issn.0376-2491.2019.36.010" @default.
• W2977189738 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31550814" @default.
• W2977189738 hasPublicationYear "2019" @default.
• W2977189738 type Work @default.
• W2977189738 sameAs 2977189738 @default.
• W2977189738 citedByCount "2" @default.
• W2977189738 countsByYear W29771897382021 @default.
• W2977189738 countsByYear W29771897382023 @default.
• W2977189738 crossrefType "journal-article" @default.
• W2977189738 hasAuthorship W2977189738A5000057889 @default.
• W2977189738 hasAuthorship W2977189738A5007398061 @default.
• W2977189738 hasAuthorship W2977189738A5027112610 @default.
• W2977189738 hasAuthorship W2977189738A5057258673 @default.
• W2977189738 hasConcept C121608353 @default.
• W2977189738 hasConcept C126322002 @default.
• W2977189738 hasConcept C141071460 @default.
• W2977189738 hasConcept C143998085 @default.
• W2977189738 hasConcept C197934379 @default.
• W2977189738 hasConcept C2776694085 @default.
• W2977189738 hasConcept C2778822529 @default.
• W2977189738 hasConcept C2779013556 @default.
• W2977189738 hasConcept C2780739268 @default.
• W2977189738 hasConcept C526805850 @default.
• W2977189738 hasConcept C71924100 @default.
• W2977189738 hasConcept C90924648 @default.
• W2977189738 hasConceptScore W2977189738C121608353 @default.
• W2977189738 hasConceptScore W2977189738C126322002 @default.
• W2977189738 hasConceptScore W2977189738C141071460 @default.
• W2977189738 hasConceptScore W2977189738C143998085 @default.
• W2977189738 hasConceptScore W2977189738C197934379 @default.
• W2977189738 hasConceptScore W2977189738C2776694085 @default.
• W2977189738 hasConceptScore W2977189738C2778822529 @default.
• W2977189738 hasConceptScore W2977189738C2779013556 @default.
• W2977189738 hasConceptScore W2977189738C2780739268 @default.
• W2977189738 hasConceptScore W2977189738C526805850 @default.
• W2977189738 hasConceptScore W2977189738C71924100 @default.
• W2977189738 hasConceptScore W2977189738C90924648 @default.
• W2977189738 hasIssue "36" @default.
• W2977189738 hasLocation W29771897381 @default.
• W2977189738 hasOpenAccess W2977189738 @default.
• W2977189738 hasPrimaryLocation W29771897381 @default.
• W2977189738 hasRelatedWork W1908989187 @default.
• W2977189738 hasRelatedWork W1970423756 @default.
• W2977189738 hasRelatedWork W1971638713 @default.
• W2977189738 hasRelatedWork W2071894746 @default.
• W2977189738 hasRelatedWork W2379424545 @default.
• W2977189738 hasRelatedWork W2419399195 @default.
• W2977189738 hasRelatedWork W2465617904 @default.
• W2977189738 hasRelatedWork W2907419770 @default.
• W2977189738 hasRelatedWork W2966452281 @default.
• W2977189738 hasRelatedWork W4229076162 @default.
• W2977189738 hasVolume "99" @default.
• W2977189738 isParatext "false" @default.
• W2977189738 isRetracted "false" @default.
• W2977189738 magId "2977189738" @default.
• W2977189738 workType "article" @default.